GuruFocus · GMAB · October 25, 2026

Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer

Get the app for more

Explore stock news, insights and company research.